A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Conditions
Chronic Lymphocytic Leukemia · CLL · Mantle Cell Lymphoma · MCL
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Genesiscare St Andrews, Adelaide, South Australia, Australia
Cabrini Hospital Malvern, Malvern, Victoria, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
Rockingham Hospital, Cooloongup, Western Australia, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Chu Dijon, Dijon, France
Chu Montpellier Hopital Saint Eloi, Montpellier, France
Iuct Oncopole, Toulouse, France
Queen Elizabeth Hospital, Birmingham, United Kingdom
St Jamess University Hospital, Leeds, United Kingdom
Study leads
Study Director
BeOne Medicines